Quote is story on etrade... sounds like two different meetings!..again barrons paints negative picture of everything Gilead. I wonder who bought those 40,000+ $120 puts??? someone is going to lose serious money if those become worthless., Like they paid $12 each so 40,000 puts is 4 millions shares time $12 .,.mnany many millions... someone is still trying to diss the company
There are two lawsuits now....it will be class action no doubt....first case of liver cance while waiting for "medical necessity" will be a big one
I just buy before it goes up and sell before it goes down...otherwise holdit long term
QQQ .. tanked 50cent in minuts...and futures tanked.....anyone know anything
YOU were the one accumulating stock at those low prices....you bt back billions of dollars of your own stock u dog...$.3 billion in the first quarter alone....probab ly already bt another $3 bil so far this quarter....
It will be good when prescription start trending up again as they will....a lot of "the press" will be surprised by that.
why should i pay a lot more for the same item?? Its not a question of "afford".....can u afford to throw your money down the toilet?...maybe u can... thats why so many young folks are always broke i guess
April 8, 2015
02:34 pm ET ... S&P CAPITAL IQ KEEPS BUY RECOMMENDATION ON SHARES OF
RITE AID (RAD 8.81****): We keep our 12-month target of $10, assuming an
EV/EBITDA of 12X, in line with peers, and our FY 16 (Feb.) EBITDA estimate of $1.3
billion. WE LOWER our FY 16 EPS estimate $0.31 to $0.17 on higher expected taxes.
Feb-Q adjusted EPS of $0.12 vs. $0.05 is $0.04 above our estimate. We see FY 16
margin support on improved generic drug purchasing and an acceleration in
generic drug sales, despite intense drug reimbursement pressure and poor near
term generic sales visibility. **
and all their stuff really up there. With Target following Walmart opening small neighborhood stores, seems like a lot of competition coming up for Rite Aid...a pharmacy on every corner in san diego.
Express Scripts made the deal Dec 22, 2014 giving Abbvie exclusive acces for treating its hep c patiens. Part of the deal was to increase access to all pts with hep c type 1 regardless of severity of disease....
Here is quote..That was the big selling point of the deal...the part that 'made up" for loss of pt choice.
""Under the deal, patients infected with genotype 1--the most common strain of hepatitis C--will be steered to AbbVie's cocktail beginning January 1. Patients already in treatment with Gilead's drugs can continue. Because AbbVie's drugs are only approved for genotype 1 disease, Express Scripts will cover Gilead's meds in patients with other genotypes. The deal applies to the 25 million people covered under Express Scripts' National Formulary.
****The agreement also allows ALL PATIENTS ACCESS to treatment,REGARDLESS OF SEVERITY of their disease. Like other payers, Express Scripts had been trying to limit its hep C spending by focusing on patients in advanced stages of hepatitis C.""***
Many pundits liked the deal because it increased access to ALL hepc type one pts...
BUT..during ABBV "posted just $138 million in U.S. Viekira Pak sales last quarter, AbbVie reported recently, falling short of the $236 million analysts expected."
WHY were so few treated during Q1?Here are my ideas...any of you out there have other possibilities??
1) because express scripts reneged and refused ton treat all type 1 pts.
2) because patients/doc refused viuekira pak
3 Beacuse somethinG is wrong with Viekira Pak from clinical standpoint.....I have heard that Express script, for some reason, wont divulge the nubers of prescription to Symphony or IMS..So what are they hiding. ??
i think congress will finally understand why it is important financially to cure those vets.....Sanders lays out the numbers for liver transplants and cancer....congress will to think about this while debating provision of $400 mil more for hepc drugs. Furthermore congress will realize that those tranbsplanted patiens will still need to be cured for their hepc after the transplant..It would cost about $400 mil just to do the liver transplants...duh..
It's just the option expiration doing this...there were like 40K + calls at 110 strike,,, that means the folks that wrote those calls would have lost a bundle if GILK had closed over $110....its worth it for those call writers to short the stock today to keep it below $110. There were a lot of $105 calls too, but GILD blew past $105. Writers off say 10,000 $105 calls,,,,had to pay off $4.30 per call today...the $ 4,300,000 ....that's what that guy talking about the "pin" is talking about
The options killed any rally over 110.....there were around 40,000 calls at $110.
and liver transplants could be expected if the 20,000 veterans weren't funded for treatrment.
""In fact, Sloan Gibson, the VA Deputy Secretary, yesterday wrote a letter to Richard Blumenthal, the ranking member of the Senate Committee on Veterans Affairs, for permission to repurpose another $400 million in its budget for the drugs.
The VA spokesman says the extra funds would be sufficient to treat between 5,000 and 10,000 vets with cirrhosis depending on the treatment and duration required. As a result, up to 4,500 new cases of liver cancer and as many as 900 liver transplants – over time – could be prevented."""
This is the kind of publicity that is needed. I think Gilead is smart to stay quiet as these facts will continue to come out over time... expecially as many baby boomers discoverf that they have the disease.
How can anyone say Gilead is profiteering too much... stock is at measily 10 to 1 p/e..
again....i wonder if their NASH drug is any good.?